- The Global Atopic Dermatitis Market was valued at USD 6.54 Billion in 2021
- It is anticipated to reach USD 16.23 Billion by 2028
- A CAGR of 13.87% is anticipated over the forecast period
Atopic dermatitis is also called as eczema. Atopic dermatitis is a condition that makes the skin red as well itchy. It's normal in kids yet can happen at whatever stage in life. No treatment has been found for atopic dermatitis. However, medicines and self-care measures can relieve itching and prevent new flare-ups.
Atopic dermatitis has different examples relying upon the age of patients. It can happen in the sides of the neck, wrists, and knees, inside the elbows, lower legs and hands and tend to create papules which prompt rashes. It is described by low amount of filaggrin protein that permits skin to get dry and reduces its protective capacities. Also, the skin is entirely defenceless to diseases, like staphylococcal and streptococcal bacterial skin infection, herpes simplex, warts, and molluscum contagiosum.
Improving economic conditions, better healthcare infrastructures, prevalence of highly preferred drugs for treating inflammatory diseases, reimbursement policies provided by the government, improving use in skin treatment and corticosteroids are fostering the growth of atopic dermatitis market.
During Covid-19 pandemic, there is lockdown in the world which prompts the closure of assembling plants and distribution channels in everywhere on the world which badly influences the global economy and furthermore affects the demand and supply of various items. Fear of COVID-19 contamination is likewise a main factor that influences the demand of items. Apart from that, because of COVID-19 the cost of treatments of atopic dermatitis has increased. It is an extraordinary chance for some organizations like Pfizer, Novartis, Mylan, LEO PHARMA, and Sanofi which are market head of atopic dermatitis.
Some of the key players for global Atopic Dermatitis Market are -
The biologics segment currently dominates the global atopic dermatitis market by drug class and is expected to continue during the forecast period. This is due to an increase in awareness regarding treatments for the disease, as well as governments taking various initiatives to make treatments more affordable and accessible. Furthermore, new product launches and increased adoption of biological drugs in various regions are driving the segment's growth.
Furthermore, the online pharmacies segment is expected to witness a higher growth rate during the forecast period owing to the rising trend of online shopping, increasing penetration of internet and smartphone in developing countries, and growing usage of e-commerce platforms. Moreover, the convenience and easy access to drugs are also expected to aid the growth of the online pharmacies segment.
North America is expected to dominate the global atopic dermatitis market owing to the increasing prevalence of atopic disorder, well-developed technology, increasing patient with low quantity of protein filaggrin, high healthcare spending, and increasing government support for research & development in this region. Also, increasing adoption of skin aggravations like cleansers, soap, detergents, cosmetics, perfumes and even water may inflame the skin disorders.
According to National Eczema Association; in 2016, shows that around 9.6 million youngsters under the time of 18 years, which was 13% of U.S. populace, had atopic dermatitis. Also, in 2016, the United States spent around USD 314 million on wellbeing framework to treat atopic dermatitis patients. For instance; In March 2017, Regeneron/Sanofi acquired approval for Dupixent (dupilumab), the first-in-class interleukin (IL)- 4 receptor inhibitor that has set another highest quality level in the treatment of atopic dermatitis.
Asia Pacific is the quickest developing atopic dermatitis market inferable from the presence of quickly developing medical services innovation, high medical care use and huge patient population in this region. Indian Dermatology Expert Board Members (DEBM), suggested by the Skin Allergy Society of India, arranged 26 proof-based proposals for AD. In China, the general predominance of AD in 2016 is accounted for to be 12.94% by clinical finding of dermatologists. Also, rising demand for new treatment strategies in nations like India and South Korea is probably going to arise as the quickest developing market across the region.
The major factor driving the growth of global atopic dermatitis market is increasing prevalence of atopic dermatitis. Allergy of any sort plays a significant part in the existence of an individual with atopic dermatitis. This condition flares up when an individual with atopic dermatitis infection is around substances that can cause allergic reactions.
According to American College of Allergy, it mostly found in youngsters and new born babies, atopic dermatitis, is assessed to represent around 10 to 20% of those experiencing skin inflammation. Likewise, substitution of second-line and essential treatments alongside premium-valued drugs are probably going to offer abundant scope of development of the worldwide atopic dermatitis market.
In addition, supportive government initiatives and growing awareness regarding the accessibility of treatment for the illness are also supplementing the market growth. According to the National Center for Biotechnology Information; in 2015, atopic dermatitis was recorded to influence around 20% of babies and youngsters and 3% of grown-ups globally.
Initiatives taken by governments to guarantee better and more moderate treatment and the presence of positive repayment strategies are probably going to push the market. Furthermore, government funds to support research for this disease also drives the atopic dermatitis market. For instance; Companies working worldwide atopic dermatitis market are centered on taking into account the requirements of the clinical local area just as understanding pool by presenting new product and innovations.
Driving players underline on research and formative exercises and participate in acquisitions, consolidations, and coordinated efforts to make their position in the global market. The worldwide atopic dermatitis market gauges to enjoy some real success with the presentation of new treatment techniques and biologics and improvement in the diagnostics innovation.
The growing awareness of atopic dermatitis has also been a major contributor to the growth of the market, as it has led to an increase in the number of patients seeking treatment. Additionally, the emergence of new and effective treatments has also been a major factor driving the market. The introduction of new drugs, such as dupilumab, has provided an effective treatment option for severe atopic dermatitis and has been a major driver of the market.
Finally, the rising demand for personalized treatments and the growing demand for natural products are also driving the growth of the atopic dermatitis market. The growing demand for natural products, such as herbal and botanical extracts, has led to an increase in the number of products available. Additionally, the rising demand for personalized treatments has led to the development of the market.
- On April 8th, 2021; Galderma announced that the Journal of the European Academy of Dermatology and Venereology (JEADV), published full results from a post-hoc analysis of the phase 2b study of its investigational therapy, Nemolizumab, in adult patients with moderate-to-severe atopic dermatitis (MtS AD). On March 12th, Published online, results of the analyses show that Nemolizumab led to rapid and sustained improvements in itch, sleep, and skin lesions in adult patients with uncontrolled MtS AD. Nemolizumab is a monoclonal antibody plays a key role in multiple disease mechanisms in both atopic dermatitis and prurigonodularis, a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated severe itching.
|2016 - 2021
|2022 - 2029
|Market Size in 2021:
|USD 6.54 Billion
|Base year considered
|Forecast Period CAGR %:
|Market Size Expected in 2028:
|USD 16.23 Billion
|Tables, Charts & Figures:
|Novartis International AG, Astellas Pharma Inc., Pfizer Inc., Sanofi S.A., Regeneron Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc, Anacor Pharmaceuticals Inc., Bristol-Myers Squibb, Meda Pharmaceuticals, Galderma S.A., Allergan Plc., LEO Pharma, Mylan, Bayer HealthCare, Encore Dermatology, others.
|By Product Type, By Fill Material, By Application, By Distribution Channel
|North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us email@example.comJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®